* Interim analysis from the B-Clear phase IIb trial shows bepirovirsen's potential to suppress both the surface antigen and the virus of hepatitis B, leading to the possibility of functional cure
* Phase III trial evaluating bepirovirsen as a monotherapy is anticipated to start in the first half of 2023
* Exploring potential combination treatments to further reduce the global burden of chronic hepatitis B
These interim analysis data were presented today in an oral late-breaker session at the
Current treatment options have limited success in leading to functional cure, where the virus is not eliminated from the body but is at low levels that are undetectable in blood and can be controlled by the immune system without medication. The mainstay of therapy includes nucleoside/nucleotide analogues (NA) which are often taken for life because they suppress but rarely clear the virus. Bepirovirsen's unique mechanism of action works to reduce HBV replication, suppress HBsAg and stimulate the immune system. Bepirovirsen has the potential to lead to functional cure in patients with CHB.
Professor
GSK is also exploring combinations of bepirovirsen and other therapeutic modalities in the following trials. Combination treatments could increase functional cure rates in more patients, thereby further reducing the global disease burden of CHB. Trials include:
Phase IIb trial of bepirovirsen in sequential combination with pegylated interferon (PegIFN) treatment
Phase II trial of bepirovirsen in combination with GSK's chronic hepatitis B targeted immunotherapy
About the B-Clear phase IIb trial
The B-Clear phase IIb study is investigating the efficacy and safety of 12 or 24 weeks treatment with bepirovirsen in people with CHB on stable NA treatment or not on NA treatment at study start. The primary endpoints are the proportion of patients achieving HBsAg levels below the Lower Limit of Quantification (LLOQ), and HBV DNA levels below LLOQ sustained for 24 weeks without rescue medication after end of treatment with bepirovirsen.
The study consists of two parallel cohorts, one for patients receiving NA treatment and the other for patients who were not on NA. Patients from each arm were randomised to 1 of 4 treatment arms within each cohort, with treatment administered weekly with or without loading doses (LD) on days 4 and 11:
Bepirovirsen 300 mg with LD for 24 weeks;
Bepirovirsen 300 mg with LD for 12 weeks then 150 mg for 12 weeks;
Bepirovirsen 300 mg with LD for 12 weeks then placebo for 12 weeks;
Placebo with LD for 12 weeks then bepirovirsen 300 mg without LD for 12 weeks.
In both cohorts, virologic responses were observed at the end of treatment:
For those patients receiving NA treatment (n=227), 24 weeks treatment of 300 mg bepirovirsen resulted in HBsAg < LLOQ and HBV DNA < LLOQ in 28% of patients at end of treatment.
For patients not on NA (n=230), 24 weeks treatment of 300 mg bepirovirsen resulted in HBsAg < LLOQ and HBV DNA < LLOQ in 29% of patients at end of treatment.
The durability of these responses is being assessed.
Treatment-related serious adverse events (SAEs) were observed in
.
(C) 2022 M2 COMMUNICATIONS, source